Cormorant Asset Management, LP Eye Point Pharmaceuticals, Inc. Transaction History
Cormorant Asset Management, LP
- $943 Million
- Q1 2025
A detailed history of Cormorant Asset Management, LP transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 8,325,000 shares of EYPT stock, worth $85.2 Million. This represents 4.79% of its overall portfolio holdings.
Number of Shares
8,325,000
Previous 8,325,000
-0.0%
Holding current value
$85.2 Million
Previous $62 Million
27.25%
% of portfolio
4.79%
Previous 4.9%
Shares
5 transactions
Others Institutions Holding EYPT
# of Institutions
164Shares Held
72.4MCall Options Held
232KPut Options Held
207K-
Suvretta Capital Management, LLC New York, NY6.8MShares$69.6 Million1.61% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.2MShares$63.4 Million0.07% of portfolio
-
Franklin Resources Inc San Mateo, CA4.15MShares$42.5 Million0.01% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA4.09MShares$41.8 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.83MShares$39.2 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $349M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...